McMillian Michael, Nie Alex Y, Parker J Brandon, Leone Angelique, Kemmerer Michael, Bryant Stewart, Herlich Judy, Yieh Lynn, Bittner Anton, Liu Xuejun, Wan Jackson, Johnson Mark D
Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ, USA.
Biochem Pharmacol. 2004 Jun 1;67(11):2141-65. doi: 10.1016/j.bcp.2004.01.029.
Macrophage activation contributes to adverse effects produced by a number of hepatotoxic compounds. Transcriptional profiles elicited by two macrophage activators, LPS and zymosan A, were compared to those produced by 100 paradigm compounds (mostly hepatotoxicants) using cDNA microarrays. Several hepatotoxicants previously reported to activate liver macrophages produced transcriptional responses similar to LPS and zymosan, and these were used to construct a gene signature profile for macrophage activators in the liver. Measurement of cytokine mRNAs in the same liver samples by RT-PCR independently confirmed that these compounds are associated with macrophage activation. In addition to expected effects on acute phase proteins and metabolic pathways that are regulated by LPS and inflammation, a strong induction was observed for many endoplasmic reticulum-associated stress/chaperone proteins. Additionally, many genes in our macrophage activator signature profile were well-characterized PPARalpha-induced genes which were repressed by macrophage activators. A shared gene signature profile for peroxisome proliferators was determined using a training set of clofibrate, WY 14643, diethylhexylphthalate, diisononylphthalate, perfluorodecanoic acid, perfluoroheptanoic acid, and perfluorooctanoic acid. The signature profile included macrophage activator-induced genes that were repressed by peroxisome proliferators. NSAIDs comprised an interesting pharmacological class in that some compounds, notably diflunisal, co-clustered with peroxisome proliferators whereas several others co-clustered with macrophage activators, possibly due to endotoxin exposure secondary to their adverse effects on the gastrointestinal system. While much of these data confirmed findings from the literature, the transcriptional patterns detected using this toxicogenomics approach showed relationships between genes and biological pathways requiring complex analysis to be discerned.
巨噬细胞活化会导致多种肝毒性化合物产生不良反应。使用cDNA微阵列,将两种巨噬细胞激活剂脂多糖(LPS)和酵母聚糖A引发的转录谱与100种典型化合物(大多为肝毒物)产生的转录谱进行了比较。先前报道的几种可激活肝巨噬细胞的肝毒物产生了与LPS和酵母聚糖相似的转录反应,这些反应被用于构建肝脏中巨噬细胞激活剂的基因特征谱。通过逆转录聚合酶链反应(RT-PCR)对同一肝脏样本中的细胞因子mRNA进行测量,独立证实了这些化合物与巨噬细胞活化有关。除了对急性期蛋白和由LPS及炎症调节的代谢途径产生预期影响外,还观察到许多内质网相关应激/伴侣蛋白有强烈诱导。此外,我们的巨噬细胞激活剂特征谱中的许多基因是过氧化物酶体增殖物激活受体α(PPARα)诱导的特征明确的基因,而这些基因被巨噬细胞激活剂所抑制。使用氯贝丁酯、WY 14643、邻苯二甲酸二乙基己酯、邻苯二甲酸二异壬酯、全氟癸酸、全氟庚酸和全氟辛酸的训练集确定了过氧化物酶体增殖剂的共享基因特征谱。该特征谱包括被过氧化物酶体增殖剂抑制的巨噬细胞激活剂诱导基因。非甾体抗炎药(NSAIDs)构成了一个有趣的药理学类别,因为一些化合物,特别是双氟尼柳,与过氧化物酶体增殖剂共聚类,而其他几种则与巨噬细胞激活剂共聚类,这可能是由于它们对胃肠道系统产生不良反应继发内毒素暴露所致。虽然这些数据大多证实了文献中的发现,但使用这种毒理基因组学方法检测到的转录模式显示出基因与生物途径之间的关系,需要进行复杂分析才能辨别。